Connor, Clark & Lunn Investment Management (CC&L)
NXTC icon

Connor, Clark & Lunn Investment Management (CC&L)’s NextCure NXTC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,991
Closed -$264K – 1368
2022
Q3 		$264K Buy
7,991
+2,493
+45% +$127K ﹤0.01% 943
2022
Q2 		$310K Buy
5,498
+1,527
+38% +$79.7K ﹤0.01% 857
2022
Q1 		$232K Sell
3,971
-190
-5% -$11.9K ﹤0.01% 922
2021
Q4 		$300K Buy
4,161
+2,931
+238% +$245K ﹤0.01% 894
2021
Q3 		$99K Buy
+1,230
New +$108K ﹤0.01% 983

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NXTC Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of NextCure (NXTC) in Q4 2022, closing a stake of 7,991 shares — an estimated $264K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NXTC in Q3 2021 and held it in 5 quarters. The position peaked at $310K in Q2 2022. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining NextCure position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 7,991 NextCure shares in Q4 2022, an estimated $264K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NextCure in Q3 2021 and held it in 5 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s NextCure position peaked at $310K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held NextCure as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.